Holen Sie sich die Stockscreener-App
1.70
7.10%
-0.13
Propanc Biopharma Inc Aktie (PPCB) Neueste Nachrichten
Propanc Biopharma, Inc. SEC 10-K Report - TradingView
Crypto and Cancer: How Biotech’s New Strategy Is Turning Heads - The Globe and Mail
Reviewing Immatics (NASDAQ:IMTX) & Propanc Biopharma (OTCMKTS:PPCB) - Defense World
Propanc receives US patent for proenzyme cancer treatment composition By Investing.com - Investing.com South Africa
Propanc receives US patent for proenzyme cancer treatment composition - Investing.com
Propanc Biopharma Receives Certificate of Grant for 'Proenzyme Composition” Patent from US Patent & Trademark Office - The Manila Times
Propanc Biopharma Receives Certificate of Grant for - GlobeNewswire
$111.2B Market Opportunity: Propanc's Non-Toxic Cancer Drug PRP Receives Critical USPTO Patent - Stock Titan
Propanc Biopharma announces plan to acquire $100 million of Ethereum - MSN
Propanc to acquire $100M of Ethereum to accelerate pipeline - BioWorld MedTech
Propanc Biopharma’s $100M Ethereum Allocation: A Strategic Gamble or a Path to Growth? - AInvest
Propanc Biopharma, Inc. Announces $100 Million Ethereum Acquisition Plan to Enhance Growth and Diversification Strategy - Quiver Quantitative
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum - The Manila Times
$100M Ethereum Investment: Cancer Drug Developer Propanc Makes Bold Move into Crypto for Growth Strategy - Stock Titan
Propanc Biopharma Secures $4 Million in Public Offering to Advance Cancer Stem Cell Research - citybuzz -
D. Boral Capital Leads Propanc Biopharma's $4,000,000 Uplisting on Nasdaq - AInvest
D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting - Newswire.com
Propanc Biopharma raises $4 million in Nasdaq debut, plans cancer trials - Investing.com
Propanc Biopharma shares fall 3.26% after-hours following shareholder update on corporate developments and Phase 1B study. - AInvest
Propanc Biopharma provides shareholder update - MarketScreener
Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 By Investing.com - Investing.com South Africa
Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 - Investing.com Nigeria
Propanc Biopharma Provides Shareholder Update - The Manila Times
Propanc Biopharma Announces Shareholder Update and 2025/26 Forecast. - AInvest
Propanc Biopharma: Recent IPO and Up-listing to Nasdaq, Advancing Lead Asset to Phase 1B Study - AInvest
$18.1B Market Potential: Propanc's Novel Cancer Drug PRP Heads to Human Trials After Successful Nasdaq IPO - Stock Titan
Propanc Biopharma Completes Public Offering on Nasdaq - MSN
Propanc Biopharma opens at $4.00 in Nasdaq uplisting - MSN
Biotech’s Big Bang: IPOs, Uplists, and the Short Squeeze Effect - The Globe and Mail
PPCB: Is Recent Nasdaq Uplisting a Game-Changer? - StocksToTrade
Propanc Biopharma’s Surging Market Debut: What’s Next? - timothysykes.com
Stocks Moving Premarket: NBY, AUDD, PPCB And Other Gainers & Losers - RTTNews
Propanc Biopharma shares rise 34.88% premarket after closing a $4 million public offering. - AInvest
Propanc Biopharma closes public offering, uplists to NASDAQ - MSN
Propanc Biopharma Stock Soars 51.23% on Capital Raise - AInvest
Propanc Biopharma shares rise 61.58% premarket after closing a $4 million public offering. - AInvest
Why Did Propanc Biopharma Stock Soar 27.25%? - AInvest
Propanc Biopharma Announces Nasdaq Uplisting, $4M Public Offering - AInvest
Propanc Biopharma shares rise 19.89% after-hours after closing a $4 million public offering. - AInvest
Propanc Biopharma shares rise 21.20% after-hours after closing a $4 million public offering. - AInvest
Propanc Biopharma Raises $4M Through Public Offering, Begins Trading on NASDAQ - AInvest
Propanc Biopharma's NASDAQ Uplisting: A Strategic Leap in Immuno-Oncology's High-Stakes Arena - AInvest
Propanc Biopharma closes $4 million public offering, lists on Nasdaq - Investing.com
Propanc Biopharma closes $4 million public offering, lists on Nasdaq By Investing.com - Investing.com UK
Propanc Biopharma raises $4 million in underwritten public offering. - AInvest
Propanc Biopharma Completes Public Offering, Uplisted to NASDAQ - AInvest
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ - MarketScreener
Cancer Treatment Developer Propanc Biopharma Raises $4M in IPO, Achieves Major Nasdaq Uplisting Milestone - Stock Titan
Propanc Biopharma Plunges 15.04% Amid Tariff Fears - AInvest
Why Propanc stock Is Tumbling In Premarket Today - Asianet Newsable
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):